Esperion Therapeutics Stock

Esperion Therapeutics Dividend 2024

Esperion Therapeutics Dividend

0 USD

Esperion Therapeutics Dividend yield

Ticker

ESPR

ISIN

US29664W1053

WKN

A1W1SJ

How much dividend does Esperion Therapeutics 2024 pay?

According to the latest status from September 2024, Esperion Therapeutics paid a total of 0 USD per share in dividends within the last 12 months. With the current Esperion Therapeutics price of 1.61 USD, this corresponds to a dividend yield of 0 %. A dividend is paid times per year.

=

Historical Esperion Therapeutics Dividends

A dividend is paid times per year. Last year, the payout months were and .

PaydateDividend

Is the Esperion Therapeutics Dividend Safe?

Esperion Therapeutics has been increasing the dividend for 0 years.

Over the past 10 years, Esperion Therapeutics has increased it by an annual 0 %.

Over a five-year period, the distribution increased by 0%.

Analysts expect a Dividend Cut of -100% for the current fiscal year.

Dividend Details

Understanding Esperion Therapeutics's Dividend Distributions

Esperion Therapeutics’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining Esperion Therapeutics's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

Esperion Therapeutics's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in Esperion Therapeutics’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

Esperion Therapeutics Aktienanalyse

What does Esperion Therapeutics do?

Esperion Therapeutics Inc is a company specialized in researching and developing innovative therapies for the treatment of heart diseases. It was founded in 2008 and is headquartered in Ann Arbor, Michigan. History: The founding of Esperion is closely connected with the history of another pharmaceutical company, Pfizer. In 2003, Pfizer introduced the drug Lipitor, used for treating high cholesterol levels. Lipitor quickly became one of the most successful medications worldwide, generating billions in revenue over the following years. Esperion Therapeutics Inc was founded to develop an alternative to Lipitor that would be better tolerated and potentially more effective. The company relied on the expertise of Dr. Roger Newton, the former research director at Pfizer involved in the development of Lipitor. Business model: Esperion's business model is based on acquiring patents for new compounds and then investigating these compounds in clinical trials. If a compound shows promise, Esperion can apply for approval from the US Food and Drug Administration (FDA) and bring the medication to market. The company has also formed a partnership with Daiichi-Sankyo to market its products in Japan and other Asian countries. Segments: Esperion focuses on developing therapies for the treatment of hyperlipidemia, or high cholesterol levels. This means the company develops medications that lower LDL cholesterol levels and reduce the risk of heart and vascular diseases. One promising compound from Esperion is ETC-1002. This medication is currently being tested in clinical trials and has the potential to be an effective alternative to conventional statins, as it does not have the same undesired effects. Other products: Esperion also has a division called Esperion Diabetes Solutions, which focuses on developing therapies for the treatment of type 2 diabetes. However, this is still in the development stage. Additionally, the company has another compound in clinical development called Bempedoic Acid. This medication acts at the cellular level to inhibit cholesterol synthesis in the body. Conclusion: Esperion Therapeutics is a company specializing in the development of innovative therapies for the treatment of heart diseases. The company focuses on lowering LDL cholesterol levels and reducing the risk of heart and vascular diseases. Esperion's promising product is ETC-1002, which has the potential to be an effective alternative to conventional statins. Through its partnership with Daiichi-Sankyo, the company also has access to Asian markets. Esperion Therapeutics is one of the most popular companies on Eulerpool.com.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Frequently Asked Questions about Esperion Therapeutics stock

How much dividend does Esperion Therapeutics pay?

Over the past 12 months, Esperion Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Esperion Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Esperion Therapeutics?

The current dividend yield of Esperion Therapeutics is .

When does Esperion Therapeutics pay dividends?

Esperion Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Esperion Therapeutics?

Esperion Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Esperion Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Esperion Therapeutics located?

Esperion Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Esperion Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Esperion Therapeutics from 9/27/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Esperion Therapeutics pay the last dividend?

The last dividend was paid out on 9/27/2024.

What was the dividend of Esperion Therapeutics in the year 2023?

In the year 2023, Esperion Therapeutics distributed 0 USD as dividends.

In which currency does Esperion Therapeutics pay out the dividend?

The dividends of Esperion Therapeutics are distributed in USD.

Andere Kennzahlen von Esperion Therapeutics

Our stock analysis for Esperion Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Esperion Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.